ValuEngine upgraded shares of CytoDyn Inc (NASDAQ:CYDY) from a strong sell rating to a sell rating in a report issued on Thursday.

A number of other analysts have also commented on CYDY. HC Wainwright set a $2.00 price objective on shares of CytoDyn and gave the stock a buy rating in a research report on Thursday, August 10th. Zacks Investment Research raised shares of CytoDyn from a sell rating to a hold rating in a research report on Wednesday, July 19th.

CytoDyn (CYDY) opened at 0.66 on Thursday. The stock’s 50 day moving average is $0.70 and its 200 day moving average is $0.65. The firm’s market cap is $100.82 million. CytoDyn has a 52 week low of $0.46 and a 52 week high of $0.85.

TRADEMARK VIOLATION WARNING: “CytoDyn Inc (CYDY) Raised to “Sell” at ValuEngine” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at

CytoDyn Company Profile

CytoDyn Inc is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for CytoDyn Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn Inc and related stocks with our FREE daily email newsletter.